Abbisko Cayman Limited (2256.HK)
Develops cancer and rare disease drugs in clinical testing across China and Europe
9.92-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-2.4%
The outlook
Analysts are notably bullish on 2256.HK, with a strong buy consensus and an average price target implying roughly 118% upside from current levels. However, the stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range, reflecting weak recent momentum. The disconnect between analyst sentiment and price action suggests cautious investor interest despite the favorable research outlook.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target +118% vs current price
Analyst price target
~12-month · 6 analysts21.63average target+118.1% vs now
Now 9.92
Low 17.56High 25.14
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.12B
52-wk high
19.78
52-wk low
8.34
50-day avg
10.05
200-day avg
12.59
Trailing P/E
99.2